| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
Kenvue Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$375.00 |
| 52 Week High | US$375.00 |
| 52 Week Low | US$375.00 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 0% |
Recent News & Updates
Recent updates
Shareholder Returns
| KVUE * | MX Personal Products | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how KVUE * performed against the MX Personal Products industry.
Return vs Market: Insufficient data to determine how KVUE * performed against the MX Market.
Price Volatility
| KVUE * volatility | |
|---|---|
| KVUE * Average Weekly Movement | n/a |
| Personal Products Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: KVUE * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine KVUE *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2022 | 22,000 | Thibaut Mongon | www.kenvue.com |
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee’s, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Kenvue Inc. Fundamentals Summary
| KVUE * fundamental statistics | |
|---|---|
| Market cap | Mex$619.17b |
| Earnings (TTM) | Mex$28.53b |
| Revenue (TTM) | Mex$264.81b |
21.7x
P/E Ratio2.3x
P/S RatioIs KVUE * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KVUE * income statement (TTM) | |
|---|---|
| Revenue | US$15.44b |
| Cost of Revenue | US$6.80b |
| Gross Profit | US$8.64b |
| Other Expenses | US$6.98b |
| Earnings | US$1.66b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | 0.87 |
| Gross Margin | 55.96% |
| Net Profit Margin | 10.77% |
| Debt/Equity Ratio | 73.9% |
How did KVUE * perform over the long term?
See historical performance and comparisonDividends
4.2%
Current Dividend Yield44%
Payout RatioDoes KVUE * pay a reliable dividends?
See KVUE * dividend history and benchmarks| Kenvue dividend dates | |
|---|---|
| Ex Dividend Date | May 07 2024 |
| Dividend Pay Date | May 22 2024 |
| Days until Ex dividend | 5 days |
| Days until Dividend pay date | 20 days |
Does KVUE * pay a reliable dividends?
See KVUE * dividend history and benchmarks